- Home
- ORIC vs PHAR Comparison
ORIC vs PHAR Comparison
Compare ORIC & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORIC
- PHAR
- Stock Information
- Founded
- ORIC 2014
- PHAR 1988
- Country
- ORIC United States
- PHAR Netherlands
- Employees
- ORIC N/A
- PHAR N/A
- Industry
- ORIC Biotechnology: Pharmaceutical Preparations
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- ORIC Health Care
- PHAR Health Care
- Exchange
- ORIC Nasdaq
- PHAR Nasdaq
- Market Cap
- ORIC 735.3M
- PHAR 618.3M
- IPO Year
- ORIC 2020
- PHAR N/A
- Fundamental
- Price
- ORIC $12.31
- PHAR $8.74
- Analyst Decision
- ORIC Strong Buy
- PHAR Strong Buy
- Analyst Count
- ORIC 9
- PHAR 3
- Target Price
- ORIC $18.75
- PHAR $27.00
- AVG Volume (30 Days)
- ORIC 825.1K
- PHAR 5.6K
- Earning Date
- ORIC 03-10-2025
- PHAR 03-13-2025
- Dividend Yield
- ORIC N/A
- PHAR N/A
- EPS Growth
- ORIC N/A
- PHAR N/A
- EPS
- ORIC N/A
- PHAR N/A
- Revenue
- ORIC N/A
- PHAR $285,745,000.00
- Revenue This Year
- ORIC N/A
- PHAR $20.08
- Revenue Next Year
- ORIC N/A
- PHAR $9.22
- P/E Ratio
- ORIC N/A
- PHAR N/A
- Revenue Growth
- ORIC N/A
- PHAR 30.64
- 52 Week Low
- ORIC $6.33
- PHAR $6.65
- 52 Week High
- ORIC $16.65
- PHAR $13.20
- Technical
- Relative Strength Index (RSI)
- ORIC 59.70
- PHAR 40.05
- Support Level
- ORIC $9.95
- PHAR $7.95
- Resistance Level
- ORIC $12.01
- PHAR $9.35
- Average True Range (ATR)
- ORIC 0.86
- PHAR 0.52
- MACD
- ORIC 0.04
- PHAR -0.16
- Stochastic Oscillator
- ORIC 64.50
- PHAR 22.76
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.